NESS-040C5
 | |
| Systematic (IUPAC) name | |
|---|---|
|
N-(2-isopropyl-5-methylcyclohexyl)-1-(4-methylbenzyl)-1,4-dihydrothieno[3',2':4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide | |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 1445751-90-5 |
| ATC code | None |
| Chemical data | |
| Formula | C27H33N3OS |
| Molar mass | 447.64 g/mol |
| |
NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma.[1] It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor.[2]
See also
References
- ↑ Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218
- ↑ Hanus LO, Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Current Medicinal Chemistry. 2010;17(14):1341-59. PMID 20166928
This article is issued from Wikipedia - version of the Friday, February 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.